A carregar...
Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
AIMS/INTRODUCTION: Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of drugs for the treatment of type 2 diabetes mellitus that improve control of plasma glucose and bodyweight, giving great hope for the clinical utility of these agents. However, it is unclear for which patients SGL...
Na minha lista:
| Publicado no: | J Diabetes Investig |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6031493/ https://ncbi.nlm.nih.gov/pubmed/29032638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12761 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|